Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells.
about
TRAIL activates JNK and NF-κB through RIP1-dependent and -independent pathwaysAn intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI)Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosisErlotinib-Conjugated Iron Oxide Nanoparticles as a Smart Cancer-Targeted Theranostic Probe for MRIA Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation.BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.TRAIL in cancer therapy: present and future challenges.Modeling dynamics of cell-to-cell variability in TRAIL-induced apoptosis explains fractional killing and predicts reversible resistanceSpongiatriol inhibits nuclear factor kappa B activation and induces apoptosis in pancreatic cancer cellsTrichothecin induces cell death in NF-κB constitutively activated human cancer cells via inhibition of IKKβ phosphorylation.A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase.Targeting AML through DR4 with a novel variant of rhTRAILThe marine natural product microsclerodermin A is a novel inhibitor of the nuclear factor kappa B and induces apoptosis in pancreatic cancer cells.The Association of CXC Receptor 4 Mediated Signaling Pathway with Oxaliplatin-Resistant Human Colorectal Cancer Cells.A Subpopulation of the K562 Cells Are Killed by Curcumin Treatment after G2/M Arrest and Mitotic Catastrophe.DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.Inhibition of NF-κB Pathway and Modulation of MAPK Signaling Pathways in Glioblastoma and Implications for Lovastatin and Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Combination Therapy.Targeting signal transduction in pancreatic cancer treatment.Antioxidant function of isoflavone and 3,3'-diindolylmethane: are they important for cancer prevention and therapy?Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapyDelivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effectsThe generation, detection, and effects of reactive drug metabolites.Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family.Targeting TRAIL in the treatment of cancer: new developments.c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells.The Gβ5 protein regulates sensitivity to TRAIL-induced cell death in colon carcinoma.Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cellsAW00179 potentiates TRAIL-mediated death of human lung cancer H1299 cells through ROS-JNK-c-Jun-mediated up-regulation of DR5 and down-regulation of anti-apoptotic molecules.TRADD is critical for resistance to TRAIL-induced cell death through NF-κB activation.The 'N-factors' in pancreatic cancer: functional relevance of NF-κB, NFAT and Nrf2 in pancreatic cancer.Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatinRole of reactive oxygen species in brucein D-mediated p38-mitogen-activated protein kinase and nuclear factor-kappaB signalling pathways in human pancreatic adenocarcinoma cells.ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosisMnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release.Targeting nuclear factor-kappa B to overcome resistance to chemotherapy.Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy.The regulation of combined treatment-induced cell death with recombinant TRAIL and bortezomib through TRAIL signaling in TRAIL-resistant cells.
P2860
Q28384960-D28458B6-871F-4A06-89D0-4278414D63EDQ28485864-A3FCD40B-78DA-4F2F-A22A-1D3D1A7D66F5Q28729017-396171BB-77B7-4195-B644-A55F61178DD8Q30828291-4AACCEB3-E569-4B25-BA47-E263B054D08FQ33515420-1AE79763-C911-4D2B-ADB5-C1C12591DD77Q33842416-01FB6CDD-6941-4E18-9BB3-B96CCF71C593Q33978723-61BF7FDD-615F-4900-8BB5-D87A14B5BA00Q34168023-0CEB5750-9706-4DA0-A006-8E326C5FA1BDQ34291312-26FB7EDE-1F96-4B84-A0F6-C71A27504921Q34393708-7168ADFA-EE30-4579-9A81-940EC4D5579DQ34645863-B8B85F80-A807-4AE2-85F3-F7EFCF2034DEQ34926660-4E3386CB-4055-4910-A74C-9D684F7632B8Q35038107-BDA4A58D-889E-4617-8EE6-226EA63D9726Q35377418-A4FC7D74-8BCE-4E9B-988B-709675E92413Q35443211-5C7E0852-EB81-4F8E-997C-D9A80D32F912Q36144732-6939BDA9-8C77-4946-B54F-DA8287DCA05DQ36188696-395F25CA-589A-4A0D-96C4-82BC4770599DQ36215003-AEBD9666-D98A-4990-9DE1-F5ECA1E1F79CQ36263997-5E2B0093-E215-4BA8-B8D3-81B6F725F3E4Q36804444-CE3F559B-3ABF-4E40-91CA-4AB6984EDE63Q36945706-E5FF7476-6A75-49EE-82C4-040123B18144Q37071019-7BFE4C21-BCDD-4EF8-9B6A-A4EF4120C2A5Q37073589-05DAB588-45D7-4260-B789-8B2B03DAB78EQ38054629-5A0A9869-E56C-4F0E-9F89-900A46DCDF01Q38098380-21F86E8D-4AD9-4CD1-B02B-95F0780CBB91Q38500801-CC70D874-2B36-4EE6-B518-221B93D1A620Q38949421-DF7BA558-6D3D-4DD7-BACA-641A1D22E11BQ38973682-CD807085-E5B2-422A-84A1-D88E2D3CE229Q39011040-A2C5CD8B-A579-45E1-AB35-4FD9C595CC8CQ39392672-20B0852D-D65B-41D1-B4C5-11158DAD6576Q39533119-5574FA27-A78B-4BD1-AA0B-BFB8AF7DFD8AQ39670791-77599DC5-B7C3-4AE6-9476-70E87534F8F9Q39710105-B5240B96-2516-4EBF-A888-13DCB3FA500DQ39752726-B0E27DC7-2E9D-4350-9551-FF884407DA9CQ39965483-BB9811A3-0D6E-449F-9F05-B378963E7966Q40102576-6BA9F8BF-B77E-4DE8-A997-5A668A7837F4Q40751673-29DD71F5-4FEA-4222-A195-4BDE9431E687Q42713862-D1A507E3-86F6-4BDB-BB49-16AB4CB2B722Q51760860-D069731C-4A62-43F8-AAD0-66C43B5A4FC0Q55181844-28F326D1-6E6A-47DA-9841-31802FCCF857
P2860
Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Constitutively activated nucle ...... protein in human cancer cells.
@en
type
label
Constitutively activated nucle ...... protein in human cancer cells.
@en
prefLabel
Constitutively activated nucle ...... protein in human cancer cells.
@en
P1476
Constitutively activated nucle ...... protein in human cancer cells
@en
P2093
Chirlei Büneker
Susanne J Braeuer
P304
P356
10.1158/1541-7786.MCR-05-0231
P577
2006-10-01T00:00:00Z